juvederm ultra xc solution for injection
allergan new zealand ltd - hyaluronic acid, lidocaine - solution for injection - indicated for use in filling of medium size depressions of the skin via mid dermis injection and to create definition and pouting of lips.
juvederm voluma solution for injection 20mg/ml
allergan new zealand ltd - hyaluronic acid - solution for injection - 20mg/ml
juvederm voluma with lidocaine solution for injection
allergan new zealand ltd - hyaluronic acid, lidocaine - solution for injection - injectable gel implant intended to restore the volume of the face. the presence of lidocaine reduces patient pain during the treatment
juvederm voluma xc solution for injection
allergan new zealand ltd - hyaluronic acid, lidocaine - solution for injection - injectable gel implant intended to restore the volume of the face. the presence of lidocaine reduces patient pain during the treatment.
vallergan 10 milligram tablets
sanofi-aventis ireland limited t/a sanofi - trimeprazine tartare - tablets - 10 milligram
vallergan 7.5 mg/5ml syrup
sanofi-aventis ireland limited t/a sanofi - trimeprazine tartare - syrup - 7.5 mg/5ml
vallergan forte 30 mg/5ml syrup
sanofi-aventis ireland limited t/a sanofi - trimeprazine tartare - syrup - 30 mg/5ml
avage cream 0.1% w/w
allergan singapore pte. ltd. - tazarotene - cream - 0.1% w/w
latisse (bimatoprost ophthalmic solution) 0.03%
allergan singapore pte. ltd. - bimatoprost - solution, sterile - 0.3mg/ml
kadian- morphine sulfate capsule, extended release
allergan, inc. - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 10 mg - kadian is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. limitations of use : - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations [see warnings and precautions ( 5.1 )] , reserve kadian for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. - kadian is not indicated as an as-needed (prn) analgesic. kadian is contraindicated in patients with: - significant respiratory depression [see warnings and pre cautions ( 5.3 )] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [s ee warnings and precautions ( 5.6 )] - concurrent use